Encinitas, CA – According to filings with the U.S. Securities and Exchange Commission, Ventyx Biosciences is raising $50,999,998.00 in new funding. Sources indicate as part of senior management Chief Business Officer, Christopher Krueger played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ventyx Biosciences
We are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. Ventyx now includes combined assets from three separate companies: Oppilan Pharma, targeting S1P1R, Zomagen Biosciences, targeting NLRP3 and the inflammasome, and Ventyx Biosciences, targeting TYK2.

To learn more about Ventyx Biosciences, visit http://ventyxbio.com/

Contact:
Christopher Krueger, Chief Business Officer
858-945-2393
ckrueger@ventyxbio.com
https://www.linkedin.com/in/chris-krueger-46604460/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved